Biopharmaceutical company Xeris Biopharma Holdings (Nasdaq: XERS) announced on Monday that the US Food and Drug Administration (FDA) has approved its supplemental new drug application for Gvoke VialDx.
The glucagon formulation is now authorised for use as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal movement in adult patients.
Xeris has partnered with American Regent to commercialise Gvoke VialDx in the United States. Under the agreement Xeris will supply the product, while American Regent will handle commercialisation. Financial terms were not disclosed.
Gvoke VialDx is the first concentrated, ready-to-dilute liquid glucagon available for the procedural gastroenterology market. It will be offered in 1-count and 10-count packages of 1 mg per 0.2 mL single-dose vials.
Availability is expected in the third quarter of 2025.
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
Kelun-Biotech's SKB518 granted IND clearance by US FDA
Renalytix reports real-world impact of KidneyIntelX on targeted kidney disease treatment
Intas and Accord BioPharma complete acquisition of UDENYCA (pegfilgrastim-cbqv) business
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Halozyme Therapeutics' VYVGART Hytrulo prefilled syringe for self-injection receives US FDA approval